Related Experiment Video

Updated: May 24, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Cognitive dysfunction is worse among pediatric patients with bipolar disorder Type I than Type II

Lindsay S Schenkel1, Amy E West, Rachel Jacobs

  • 1Department of Psychology, Rochester Institute of Technology, Rochester, NY 14623, USA. lssgsh@rit.edu

Journal of Child Psychology and Psychiatry, and Allied Disciplines
|February 21, 2012
PubMed

Insights

Pediatric patients with bipolar disorder (BD) show cognitive impairments. Bipolar I disorder (BD I) patients exhibit more severe deficits than Bipolar II disorder (BD II) patients, with verbal learning and memory potentially serving as a key endophenotype.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Cognitive Psychology

Background:

  • Pediatric patients with bipolar disorder (BD) consistently exhibit impaired neurocognitive function.
  • These cognitive deficits may help identify endophenotypes across different BD subtypes.
  • Understanding these profiles is crucial for targeted interventions.

Purpose of the Study:

  • To determine the distinct phenotypic cognitive profiles of pediatric patients with Bipolar I disorder (BD I) and Bipolar II disorder (BD II).
  • To compare cognitive performance between BD subtypes and healthy controls (HC).

Main Methods:

  • A cohort of 79 participants, including 27 with BD I, 19 with BD II, and 33 demographically and intellectually matched HC, completed a comprehensive neurocognitive task battery.
  • Neurocognitive domains assessed included attention, executive function, working memory, visual memory, and verbal learning and memory.

Main Results:

  • BD I patients demonstrated significantly poorer performance than HC across all cognitive domains.
  • BD I patients also performed worse than BD II patients in most cognitive domains, except working memory.
  • BD II patients showed impairments relative to HC only in verbal learning and memory.

Conclusions:

  • Pediatric BD I patients exhibit more severe cognitive impairment than BD II patients, who show intermediate performance between BD I and HC.
  • Verbal learning and memory may serve as a cognitive endophenotype, effectively differentiating pediatric BD patients from controls across subtypes.
  • These findings support the development of subtype-specific cognitive interventions for pediatric BD.
Abstract

Related Concept Videos

Bipolar Disorder01:30

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Dissociative Identity Disorder01:30

Dissociative Identity Disorder

Dissociative Identity Disorder (DID), previously termed multiple personality disorder, is a complex psychological condition characterized by the presence of two or more distinct identities or personality states. Each identity exhibits unique patterns of behavior, voice, and mannerisms and may possess separate memories and emotional responses. The alternating control between identities can result in memory gaps and challenges in recalling daily activities, often exacerbating the individual's...